A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis (UC) Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors

NCT02165215 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

359

Enrollment

INDUSTRY

Sponsor class

Conditions

Colitis, Ulcerative

Interventions

DRUG: Etrolizumab
DRUG: Placebo

Sponsor

Hoffmann-La Roche